|
Indications and Dosage
Intravenous
Malignant neoplasms Adult: 1-3 g/m2 daily for 5 days. Oral Malignant neoplasms Adult: Up to 1 g/m2 daily. Usually used with uracil. Oral Advanced colorectal cancer Adult: 300 mg/m2 tegafur combined with 672 mg/m2 uracil daily in 3 divided doses, together with calcium folinate. Doses are given for a cycle of 28 days, followed by 7 days without treatment.
|
|
Contraindications
Pregnancy, lactation. Hypersensitivity.
|
|
Special Precautions
Weak or malnourished patients, hepatic and renal impairment, history of cardiac disease, acute infections. Determine blood count frequently.
|
|
Adverse Reactions
Nausea, vomiting, anorexia, mucositis, malaise, hot flushes, oedema, itching, central neurotoxicity, bone-marrow depression, stomatitis, haemorrhage, skin rashes, alopoecia, ocular irritation, myocardial ischaemia,
|
|
Drug Interactions
Concurrent use increased risk of neurotoxicity with leflunomide; increased risk of phenytoin toxicity with phenytoin; increased anticoagulation effect of warfarin; increased risk of myelosupression with colony stimulating factors eg. filgrastim; increased risk of thrombosis with tamoxifen; increased risk of toxicity with folic acid.
Potentially Fatal: Increased risk of severe toxicity with sorivudine. |
|
Action
Description:
Mechanism of Action: Tegafur is an antineoplastic agent that acts as an antimetabolite. It is a prodrug of fluorouracil that is administered orally. Pharmacokinetics: Absorption: Well absorbed in GI tract. Distribution: Crosses the blood-brain barrier and is found in the CSF. Metabolism: Metabolised slowly in the liver to fluorouracil; some intracellular conversion to fluorouracil may also occur. Plasma half-life of 6-16 hr (IV). |
|
MIMS Class
|
Sign Out
